Hero Background


AI-enabled solutions to help identify and treat cardiovascular disease

We build solutions that leverage routinely generated clinical data to help clinicians find patients with undiagnosed or undertreated cardiovascular disease.


Tempus Next

Tempus Next is a care pathway intelligence platform that empowers providers to deliver the next step in a patient’s care journey, with the goal of improving overall outcomes for patients and fostering value based care within health systems.

Tempus Next supports clinicians in delivering best practice, guideline-directed medical care by creating awareness of gaps in care, identifying patients who have not received treatment consistent with applicable guidelines, and delivering customized and accurate guideline-directed recommendations directly within an established clinical workflow.

Our impact

  • 60+

    algorithms to identify potential care gaps across 18 cardiovascular diseases

  • 1.5M+

    patients screened

  • 70+

    hospitals nationwide are currently powered by Tempus Next

  • 40K+

    patients screened per month

image description

How it works

Identify and minimize care gaps with Tempus Next.1 With our AI-platform, you’ll experience:

Easy EHR integration

Seamlessly and securely integrates into your hospital’s EHR system to monitor cardiac patients for optimal treatment

Advanced Natural Language Processing (NLP)

Analyzes free text from clinical notes and other data sources using Advanced NLP

A true partner in excellence

Provides team support to ensure you exceed your objectives for superior care

Robust cardiac service line coverage

Encompasses a broad cardiac service line, helping care teams enable comprehensive cardiac disease care

Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, in addition to all other available patient data. Our system follows patients through progression from low severity to high severity.

Our Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation.

Within cardiomyopathies, our screening protocols address care across non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, pulmonary hypertension, and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like LVAD or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists.

Our electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.2 Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.2 Tempus Next  continuously monitors patient data to find at-risk patients, and alert the patient’s care team of any needed follow-up or disease progression.

Tempus Next also screens for an array of additional conditions including congestive heart failure, acute coronary syndrome, ischemic heart diseases, hypertension, and dyslipidemia. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.3

Our Science

view all

    Deep neural networks can predict new-onset Atrial Fibrillation from the 12-lead ECG and help identify those at risk of Atrial Fibrillation-related stroke

    Atrial fibrillation (AF) is associated with substantial morbidity, especially when it goes undetected. If new-onset AF can be predicted, targeted screening could possibly be used to find it early. In this study, we explore if a deep neural network can predict new-onset AF from the resting 12-lead ECG and study whether this prediction may help identify those at risk of AF-related stroke.

    Read more

    rECHOmmend: An ECG-based machine learning approach for identifying patients at increased risk of undiagnosed structural heart disease detectable by Echocardiography

    In this study, we developed a novel ECG-based machine learning approach to predict multiple structural heart conditions, hypothesizing that a composite model would yield higher prevalence and positive predictive values to facilitate meaningful recommendations for echocardiography.

    Read more

    Prospective evidence generation via ECG-AID Study

    We have launched a multi-site prospective study with our beta partners to test our algorithms for atrial fibrillation and structural heart disease. The study is called ‘ECG-AID’ and is expected to enroll 600-1,000 patients to validate prospective performance across multiple patient populations and data systems.

    Read more

    Machine learning analysis including social determinants of health for prediction of mortality following Transcatheter Aortic Valve Implantation: a single center experience

    Social Determinants of Health are increasingly being recognized as critical, independent prognosticators in cardiovascular disease. In this study, we explore if our ML model provides a holistic picture of mortality prediction to understand the role in care following TAVI.

    Read more

    Racial and Echocardiographic predictors of all-cause mortality in patients with moderate Tricuspid Regurgitation: a single center study

    This study assessed transthoracic echocardiography (TTE), clinical and socioeconomic (SES) factors as predictors of progression from moderate to severe tricuspid regurgitation (TR) and showed that race/TTE indices offer insights into personalized management of patients with moderate TR.

    Read more

    Enhanced detection of Heart Valve Disease using integrated artificial intelligence at scale

    This study explores our platform that uses a rules-based algorithm to search EHRs for heart valve disease among patients treated by healthcare systems in the US to help provide a solution.

    Read more

    ML-based cluster analysis of patients with significant TR reveals distinct population with different phenotypes and clinical outcomes

    In this Alan S. Pearlman Research Award Winning analysis, we uncover that significant TR is associated with considerable risk of clinical outcomes, and that a ML-based approach to identify phenogroups may aid in the timing and selection of therapy.

    Read more

    Machine learning analysis of progression from moderate to severe Tricuspid Regurgitation

    This study assessed echocardiographic (Echo) and demographic predictors of moderate TR progression using Natural Language Processing (NLP) to further support that insights from NLP can help to improve the performance of disease prediction.

    Read more

    FDA grants breakthrough device designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, developed in collaboration with Geisinger

    Tempus announced the U.S. FDA has granted Breakthrough Device Designation for its ECG Analysis Platform. Developed in collaboration with Geisinger, it aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter.

    Read more

1 Husband G.; D”amico A.; Hasnie U.; Batra N.; Cochrun S.; Gann A.; Li E.; Nguyen D.; Philip George A.; Soto M.; Rogers C.; Ahmed M.; Andrikopoulou E.; UAB Hospital, Birmingham, United States of America; University of South Alabama, Mobile, United States of America; The Johns Hopkins Hospital, Baltimore, United States of America. February 2022. European Heart Journal – Cardiovascular Imaging, Volume 23, Issue Supplement_1 [online]. Available from: https://academic.oup.com/ehjcimaging/article/23/Supplement_1/jeab289.244/6522478

2 Sudden Cardiac Arrest Foundation. January 29, 2020. Latest statistics: 1,000 people suffer sudden cardiac arrest each day in U.S.; only 10% survive [online]. Available from: https://www.sca-aware.org/sca-news/latest-statistics-1000-people-suffer-sudden-cardiac-arrest-each-day-in-us-only-10-survive [Accessed May 1, 2023]

3 J Comp Eff Res. October 2021. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/34225473/ [Accessed May 1, 2023]

Partnering with Tempus is investing in the future

We believe that AI-enabled solutions can help shorten the diagnostic odyssey and improve the lives and outcomes of patients with cardiovascular disease.